• Scinai Immunotherapeutics corrected an error in its proxy materials for the June 16, 2026 annual meeting on Proposal 6.
• The proxy statement misstated when Chairman Mark Germain’s current director term ends, describing it as the second anniversary of the meeting.
• The company clarified the term runs through the second annual shareholders’ meeting following the June 16, 2026 meeting.
• If Proposal 6 passes, Germain’s extended services agreement would expire at that later annual meeting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scinai Immunotherapeutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-066166), on June 08, 2026, and is solely responsible for the information contained therein.